Danaher Co. (NYSE:DHR) Position Reduced by Aries Wealth Management

Aries Wealth Management reduced its position in Danaher Co. (NYSE:DHR) by 2.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,221 shares of the conglomerate’s stock after selling 55 shares during the period. Aries Wealth Management’s holdings in Danaher were worth $510,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. AMF Tjanstepension AB purchased a new stake in shares of Danaher in the third quarter valued at $5,923,000. Wedge Capital Management L L P NC raised its position in Danaher by 3.2% during the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after buying an additional 38 shares during the period. CX Institutional lifted its stake in Danaher by 5.5% in the 3rd quarter. CX Institutional now owns 2,908 shares of the conglomerate’s stock worth $808,000 after acquiring an additional 151 shares in the last quarter. Creative Planning boosted its position in Danaher by 3.1% during the 3rd quarter. Creative Planning now owns 126,340 shares of the conglomerate’s stock worth $35,125,000 after acquiring an additional 3,749 shares during the period. Finally, Magnus Financial Group LLC purchased a new position in Danaher during the 3rd quarter valued at about $233,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Price Performance

NYSE DHR opened at $203.56 on Friday. Danaher Co. has a 1 year low of $196.80 and a 1 year high of $281.70. The company has a fifty day simple moving average of $230.49 and a 200 day simple moving average of $250.28. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The company has a market cap of $147.03 billion, a P/E ratio of 38.55, a P/E/G ratio of 2.68 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the previous year, the business earned $2.09 earnings per share. On average, sell-side analysts predict that Danaher Co. will post 7.67 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is currently 20.45%.

Insiders Place Their Bets

In other news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

DHR has been the subject of a number of research analyst reports. Jefferies Financial Group reduced their price target on shares of Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. Robert W. Baird cut their target price on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Wells Fargo & Company lowered their price target on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. JPMorgan Chase & Co. cut their price objective on Danaher from $310.00 to $300.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. Finally, Guggenheim began coverage on Danaher in a research note on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price on the stock. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.